Key result
Pediatric LUX-Dx ICM implantation yields a diagnostic conclusion in ~79% of patients without complications.
Why the study?
Although insertable cardiac monitors (ICMs) are increasingly used in pediatric patients, real-world data on the procedural feasibility, sensing performance, transmission burden, and user experience of new-generation devices remain limited.
Does new-generation LUX-Dx insertable cardiac monitor implantation provide safe procedural feasibility, stable sensing performance, and high diagnostic yield in pediatric patients?
Observational (n=29)
No
Does new-generation LUX-Dx insertable cardiac monitor implantation provide safe procedural feasibility, stable sensing performance, and high diagnostic yield in pediatric patients?
New-generation insertable cardiac monitor implantation in pediatric patients is safe and achieves a 79% diagnostic yield at a median of 3 months, largely aided by remote monitoring and reprogramming.
Supports safe ICM use for arrhythmia evaluation in select pediatric patients; leaves open need for prospective trials to guide broader adoption.
Background Insertable cardiac monitors (ICMs) are increasingly used in pediatric patients, yet data on new‐generation devices remain limited. The aim of this retrospective study was to describe a single‐center real‐world experience with a new‐generation ICM in pediatric patients, focusing on procedural feasibility, sensing performance, transmission burden, and user experience. Methods Consecutive patients aged ≤18 years undergoing LUX‐Dx ICM implantation between 2023 and 2025 were included. Procedural characteristics, sensing parameters, transmission patterns, diagnostic yield, reprogramming strategies, and patient/caregiver‐reported experience were analyzed. Data are reported as median (25th–75th percentile) or mean ± standard deviation. Results Twenty‐nine patients underwent ICM implantation. Procedures were brief (6 ± 2 min) and complication‐free. Electrical parameters were satisfactory and stable at discharge. Follow‐up was 18 (6–23) months. A median of 2.7 transmissions per patient‐month were received, of which 55% were alerts. Time from arrhythmia detection to transmission was 15 (3–21) hours. The number of episodes per patient was 4.8 (3.1–15.9) per month, with substantial inter‐patient variability and bradycardia being the most frequent detection (80%). A diagnostic conclusion was reached in 79% of patients (positive: 45%, negative: 34%) at a median of 3 months. Reprogramming was performed in 90% of patients, mainly remotely (77%), and was predominantly directed toward reducing detection sensitivity. Patient and caregiver acceptance of remote monitoring was high. Conclusions In pediatric patients, new‐generation ICM implantation was safe, well tolerated, and associated with stable sensing performance. Remote monitoring and reprogramming enabled timely diagnosis and individualized optimization, supporting the clinical utility of contemporary ICMs in this population.
No takes yet. Share an insight, caveat, or question.
Silvetti et al. (2026) conducted an observational in Pediatric patients requiring cardiac rhythm monitoring (n=29). LUX-Dx insertable cardiac monitor (ICM) was evaluated on Diagnostic conclusion yield.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: